Powered by

Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases; Experienced team focused initially on genetically-defined, early onset form of dementia with pot

Nov 07, 2019 - PR Newswire

PR Newswire

Arkuda Therapeutics, a company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease, today announced the completion of a $44 million Series A financing. Led by a team of drug developers and scientists with deep experience in central nervous system disorders and neurodegeneration, Arkuda's lead therapeutic approach centers on improving lysosomal function and neuronal health by increasing levels ...